Re: FDA Approved a Potent and Pricey Cholesterol lowering drug today
Epstein Suite indexes the text; the original document lives at its official source. We don't host the original file — view it on the official release to read it in full.
View the original on the official releasePeople & organizations named in this document
Being named here is not an accusation of wrongdoing.
Document text
Text is machine OCR and may contain errors. Confirm against the original source above.
From: jeffrey E. [[email protected]]
Sent: 7/24/2015 8:47:39 PM
To: Sultan Bin Sulayern
Subject: Re: FDA Approved a Potent and Pricey Cholesterol lowering drug today
yes, it requires a shot, its not a pill and so far no long term effects known
On Fri, Jul 24, 2015 at 4:37 PM, Sultan Bin Sulayem <q wrote:
Have you heard of this colestrol
Jul 24, 2015 @ 3:23 PM 1,169 views
The FDA Approves A Potent And Pricey
Cholesterol-Lowering Shot
Matthew Herper ,
Forbes Staff
I cover science and medicine, and believe this is biology's century.
e Follow on Forbes
(1970)
° Full Bio
° Recent Posts
° Popular Posts
I believe this is biology's century. I've covered science and medicine for Forbes from the Human Genome
Project through Vioxx to the blossoming DNA technology changing the world today. Email me, follow me on
Twitter, circle me onGoogle Plus, or subscribe to my Facebook page.
Loading...
Loading...
The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who
have established heart disease, for people whose risk of a heart attack or stroke is not being adequately
controlled by existing drugs called statins.
It might be a big step in the battle against heart disease — and the approval is a triumph for Regeneron
Pharmaceuticals, the Tarrytown, N.Y.-based biotechnology company that invented it. Praluent is likely to be
more widely used, and to cost more, than Wall Steet analysts expected. That also means it could be a big cost
HOUSE_OVERSIGHT_026362
Have a question about what this document contains?
Ask the documents